In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 3985-3988

  Ikubo, Shigeki ^a   Takigawa, Nagio ^a   Ueoka, Hiroshi ^a   Kiura, Katsuyuki ^a   Tabata, Masahiro ^a   Shibayama, Takuo ^a   Chikamori, Masakazu ^a   Aoe, Keisuke ^a   Matsushita, Akio ^a   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Antimicrotubule agents; Drug resistance; MTT assay; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; NAVELBINE; PACLITAXEL; RHIZOXIN; VINBLASTINE; VINCRISTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MICROTUBULE; PRIORITY JOURNAL;

EID: 0032806307     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Budmann DR: New vinca alkaloids and related compounds. Semin Oncol 19: 639-645, 1992.
2. Canobbio L, Boccardo F, Pastorino G, et al: Phase II study of navelbine in advanced breast cancer. Semin Oncol 16: 33-36, 1989.
3. DePierre A, Lemarie E, Dabouis G, et al: Efficacy of navelbine (NBR) in non-small cell lung cancer (NSCLC). Semin Oncol 16: 26-29, 1989.
4. Tsuruo T, Oh-hara T, Iida H, et al: Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cell and their vincristin-resistant sublines. Cancer Res 46: 381-385, 1986.
5. Bissett D, Graham MA, Setanoians A, et al: Phase I and pharmacokinetic study of rhizoxin. Cancer Res 52: 2894-2898, 1992.
6. Pazdur R, Kudelka AP, Kavanagh JJ, et al: The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19: 351-386, 1993.
7. Takigawa N, Ohnoshi T, Ueoka H, et al: Comparison of antitumor activity of new anthracycline analogues. ME2303, KRN8602 and SM5887 using human lung cancer cell lines. Acta Med Okayama 46: 249-256, 1992.
8. Miyamoto H: Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells. Acta Med Okayama 40: 65-73, 1986.
9. Kiura K, Ohnoshi T, Tabata M, et al: Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance. Acta Med Okayama 47: 191-197, 1993.
10. Takigawa N, Ohnoshi T, Ueoka H, et al: Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 46: 203-212, 1992.
11. Moritaka T, Kiura K, Ueoka H, et al: Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 18: 927-934, 1998.
12. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxic assays. J Im Meth 65: 55-63, 1983.
13. Sandler AB: Current management of small cell lung cancer. Semin Oncol 24: 463-478, 1997.
14. Doyle LA: Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20: 326-337, 1988.
15. Carmichael J, Mitchell JB, Degraff WG, et al: Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57: 540-547, 1988.
16. Kelland LR and Abel G: Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444-450, 1992.
17. Jensen PB, Christensen IJ, Sehested M, et al: Differential cytotoxity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer 67: 311-320, 1993.
18. Latreille J, Cormier Y, Martins H, et al: Phase 11 study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 13: 343-345, 1996.
19. Tabata M, Ohnoshi T, Ueoka H, et al: MDR1 gene expression and treatment outcome in small cell lung cancer: MDR1 gene expression as an indipendent prognostic factor. Acta Med Okayama 47: 243-248, 1993.
20. Waud WR, Harrison SD, Gilbert KS, et al: Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Phrmacol 27: 456-463, 1991.